Sol Gel Total Cash From Operating Activities Over Time
| SLGL Stock | USD 0.97 0.01 0.94% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Sol Gel Performance and Sol Gel Correlation. Sol |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sol Gel. If investors know Sol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sol Gel listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.34) | Revenue Per Share 0.235 | Quarterly Revenue Growth 8.146 | Return On Assets (0.22) | Return On Equity (0.36) |
The market value of Sol Gel Technologies is measured differently than its book value, which is the value of Sol that is recorded on the company's balance sheet. Investors also form their own opinion of Sol Gel's value that differs from its market value or its book value, called intrinsic value, which is Sol Gel's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sol Gel's market value can be influenced by many factors that don't directly affect Sol Gel's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sol Gel's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sol Gel is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sol Gel's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Cash From Operating Activities Analysis
Compare Sol Gel Technologies and related stocks such as Oric Pharmaceuticals, Lyra Therapeutics, and Inhibrx Total Cash From Operating Activities Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORIC | (20.8 M) | (20.8 M) | (20.8 M) | (20.8 M) | (20.8 M) | (20.8 M) | (20.8 M) | (20.8 M) | (20.7 M) | (23.5 M) | (45.3 M) | (59.5 M) | (75.1 M) | (85.7 M) | (81.4 M) |
| LYRA | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | (13.8 M) | (21.1 M) | (25.8 M) | (43.4 M) | (63.3 M) | (60.1 M) |
| INBX | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.1 M) | (18.8 M) | (23.1 M) | (32.1 M) | (48 M) | (80.3 M) | (115.3 M) | (193.3 M) | (183.6 M) |
| EPIX | 0.0 | 0.0 | 0.0 | (2.1 M) | (12.3 M) | (15.3 M) | (17.4 M) | (10.2 M) | (12.2 M) | (17 M) | (25.4 M) | (28.7 M) | (19.8 M) | (22.7 M) | (23.9 M) |
| SNSE | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (8.6 M) | (17.7 M) | (30.3 M) | (39 M) | (32 M) | (33.6 M) |
| NXTC | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | (12.5 M) | 8 M | (35.6 M) | (45 M) | (57.2 M) | (53.9 M) | (53 M) | (55.6 M) |
| NUVB | (616 K) | (616 K) | (616 K) | (616 K) | (616 K) | (616 K) | (616 K) | (616 K) | (616 K) | (24.4 M) | (36.5 M) | (68.2 M) | (96.1 M) | (68 M) | (71.4 M) |
| GLUE | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (6.2 M) | (23.1 M) | (59.4 M) | (92.5 M) | (43.8 M) | (46 M) |
| ERAS | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (10.4 M) | (32.7 M) | (79.6 M) | (103.3 M) | (101.2 M) | (106.3 M) |
Sol Gel Technologies and related stocks such as Oric Pharmaceuticals, Lyra Therapeutics, and Inhibrx Total Cash From Operating Activities description
My Equities
My Current Equities and Potential Positions
| Sol Gel Technologies | SLGL |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Israel |
| Exchange | NASDAQ Exchange |
USD 0.9708
Check out Sol Gel Performance and Sol Gel Correlation. You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Sol Gel technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.